Lifastuzumab vedotin - CAS 1401812-88-1

Lifastuzumab vedotin (DNIB0600A), an antibody-drug conjugate (ADC), consists of a humanized IgG1 monoclonal antibody targeting NaPi2b (MNIB2126A) linked to the potent antimitotic agent monomethyl auristatin E (MMAE), which disrupts cell division by inhibiting tubulin polymerization. This compound shows promise for research in non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) [1].

Antibody-Drug Conjugates (ADCs), Others

Others, Antibody-drug Conjugate/ADC Related

1401812-88-1

-20°C

Ice Packs

Inhibitory Antibodies